Skip to main content
NASDAQ:TPTX

Turning Point Therapeutics Competitors

$65.94
+0.99 (+1.52 %)
(As of 05/12/2021 04:30 PM ET)
Add
Compare
Today's Range
$63.86
$68.33
50-Day Range
$62.93
$103.10
52-Week Range
$52.14
$141.30
Volume699,705 shs
Average Volume382,931 shs
Market Capitalization$3.24 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.23

Competitors

Turning Point Therapeutics (NASDAQ:TPTX) Vs. GRFS, RDY, TEVA, JAZZ, BHC, and MRVI

Should you be buying TPTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Turning Point Therapeutics, including Grifols (GRFS), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), and Maravai LifeSciences (MRVI).

Grifols (NASDAQ:GRFS) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares Grifols and Turning Point Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Grifols12.79%10.65%4.79%
Turning Point TherapeuticsN/A-23.81%-23.08%

Risk & Volatility

Grifols has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Grifols and Turning Point Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Grifols03502.63
Turning Point Therapeutics00703.00

Turning Point Therapeutics has a consensus price target of $153.7143, suggesting a potential upside of 133.11%. Given Turning Point Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Turning Point Therapeutics is more favorable than Grifols.

Institutional & Insider Ownership

15.2% of Grifols shares are owned by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are owned by institutional investors. 23.2% of Turning Point Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Grifols and Turning Point Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grifols$5.71 billion2.18$700.16 million$1.1715.49
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-22.05

Grifols has higher revenue and earnings than Turning Point Therapeutics. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Summary

Grifols beats Turning Point Therapeutics on 7 of the 13 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Risk & Volatility

Dr. Reddy's Laboratories has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.

Valuation and Earnings

This table compares Dr. Reddy's Laboratories and Turning Point Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.32 billion5.13$259 million$2.7925.62
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-22.05

Dr. Reddy's Laboratories has higher revenue and earnings than Turning Point Therapeutics. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Dr. Reddy's Laboratories and Turning Point Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr. Reddy's Laboratories8.23%16.33%10.79%
Turning Point TherapeuticsN/A-23.81%-23.08%

Analyst Ratings

This is a summary of recent ratings and target prices for Dr. Reddy's Laboratories and Turning Point Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr. Reddy's Laboratories00303.00
Turning Point Therapeutics00703.00

Dr. Reddy's Laboratories currently has a consensus price target of $70.00, suggesting a potential downside of 2.06%. Turning Point Therapeutics has a consensus price target of $153.7143, suggesting a potential upside of 133.11%. Given Turning Point Therapeutics' higher possible upside, analysts clearly believe Turning Point Therapeutics is more favorable than Dr. Reddy's Laboratories.

Summary

Dr. Reddy's Laboratories beats Turning Point Therapeutics on 7 of the 12 factors compared between the two stocks.

Teva Pharmaceutical Industries (NYSE:TEVA) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

Teva Pharmaceutical Industries has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Valuation & Earnings

This table compares Teva Pharmaceutical Industries and Turning Point Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.89 billion0.66$-998,000,000.00$2.314.45
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-22.05

Turning Point Therapeutics has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Teva Pharmaceutical Industries and Turning Point Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teva Pharmaceutical Industries-24.17%19.32%4.89%
Turning Point TherapeuticsN/A-23.81%-23.08%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Teva Pharmaceutical Industries and Turning Point Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teva Pharmaceutical Industries17302.18
Turning Point Therapeutics00703.00

Teva Pharmaceutical Industries currently has a consensus target price of $11.7778, suggesting a potential upside of 14.68%. Turning Point Therapeutics has a consensus target price of $153.7143, suggesting a potential upside of 133.11%. Given Turning Point Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turning Point Therapeutics is more favorable than Teva Pharmaceutical Industries.

Summary

Turning Point Therapeutics beats Teva Pharmaceutical Industries on 7 of the 13 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Turning Point Therapeutics (NASDAQ:TPTX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

Jazz Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Valuation & Earnings

This table compares Jazz Pharmaceuticals and Turning Point Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.63$523.37 million$14.6012.05
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-22.05

Jazz Pharmaceuticals has higher revenue and earnings than Turning Point Therapeutics. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.7% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are held by institutional investors. 4.6% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Jazz Pharmaceuticals and Turning Point Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Turning Point TherapeuticsN/A-23.81%-23.08%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Jazz Pharmaceuticals and Turning Point Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111502.82
Turning Point Therapeutics00703.00

Jazz Pharmaceuticals currently has a consensus target price of $192.6250, suggesting a potential upside of 9.51%. Turning Point Therapeutics has a consensus target price of $153.7143, suggesting a potential upside of 133.11%. Given Turning Point Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turning Point Therapeutics is more favorable than Jazz Pharmaceuticals.

Summary

Jazz Pharmaceuticals beats Turning Point Therapeutics on 9 of the 13 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Turning Point Therapeutics (NASDAQ:TPTX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

Bausch Health Companies has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Valuation & Earnings

This table compares Bausch Health Companies and Turning Point Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Companies$8.60 billion1.16$-1,788,000,000.00$4.436.30
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-22.05

Turning Point Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are held by institutional investors. 12.1% of Bausch Health Companies shares are held by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Bausch Health Companies and Turning Point Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bausch Health Companies-23.92%173.20%4.21%
Turning Point TherapeuticsN/A-23.81%-23.08%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Bausch Health Companies and Turning Point Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bausch Health Companies13502.44
Turning Point Therapeutics00703.00

Bausch Health Companies currently has a consensus target price of $34.80, suggesting a potential upside of 24.64%. Turning Point Therapeutics has a consensus target price of $153.7143, suggesting a potential upside of 133.11%. Given Turning Point Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turning Point Therapeutics is more favorable than Bausch Health Companies.

Summary

Turning Point Therapeutics beats Bausch Health Companies on 7 of the 13 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Turning Point Therapeutics (NASDAQ:TPTX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Profitability

This table compares Maravai LifeSciences and Turning Point Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
Turning Point TherapeuticsN/A-23.81%-23.08%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Maravai LifeSciences and Turning Point Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
Turning Point Therapeutics00703.00

Maravai LifeSciences currently has a consensus target price of $38.3750, suggesting a potential upside of 6.07%. Turning Point Therapeutics has a consensus target price of $153.7143, suggesting a potential upside of 133.11%. Given Turning Point Therapeutics' higher possible upside, analysts plainly believe Turning Point Therapeutics is more favorable than Maravai LifeSciences.

Institutional and Insider Ownership

81.3% of Turning Point Therapeutics shares are held by institutional investors. 23.2% of Turning Point Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Maravai LifeSciences and Turning Point Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-22.05


Turning Point Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Grifols logo
GRFS
Grifols
1.3$18.12+3.0%$12.83 billion$5.71 billion16.18
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$71.47+0.4%$11.93 billion$2.32 billion59.07Upcoming Earnings
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.27+0.2%$11.19 billion$16.89 billion-2.79Analyst Report
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$175.90+1.2%$9.89 billion$2.16 billion55.49Analyst Report
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$27.92+1.8%$9.83 billion$8.60 billion-5.12
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.18+2.3%$9.11 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
United Therapeutics logo
UTHR
United Therapeutics
1.7$195.49+0.6%$8.70 billion$1.45 billion18.49Earnings Announcement
Analyst Report
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$153.18+1.7%$7.88 billion$3.34 million-19.89Earnings Announcement
Analyst Upgrade
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$49.48+0.7%$7.33 billion$40.56 million-14.51Earnings Announcement
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$68.70+1.6%$7.27 billion$87.99 million-81.79Analyst Revision
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$136.96+2.4%$7.18 billion$14.98 million-16.68Upcoming Earnings
News Coverage
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$106.40+2.0%$7.18 billion$103.71 million-24.24Analyst Report
Analyst Revision
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96+0.0%$6.86 billion$311.33 million-127.30
Perrigo logo
PRGO
Perrigo
2.2$45.76+3.1%$5.92 billion$4.84 billion-762.54Earnings Announcement
Unusual Options Activity
News Coverage
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$73.89+3.9%$5.67 billion$380.83 million-9.45Earnings Announcement
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$91.65+2.3%$5.47 billion$66.51 million16.91
Allakos logo
ALLK
Allakos
1.7$98.89+0.2%$5.30 billionN/A-36.09Earnings Announcement
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.31+1.7%$5.26 billion$1.12 billion77.73Earnings Announcement
Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$36.33+3.3%$5.14 billion$150,000.00-17.14Earnings Announcement
Unusual Options Activity
Galapagos logo
GLPG
Galapagos
1.3$74.14+0.7%$4.82 billion$1.00 billion-11.23Analyst Report
Gap Down
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$68.27+3.2%$4.37 billionN/A-5.56Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$73.88+0.4%$4.34 billion$6.87 million-7.14Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.6$59.68+3.5%$4.32 billion$85.54 million0.00Analyst Report
News Coverage
I-Mab logo
IMAB
I-Mab
1.2$62.07+5.3%$4.25 billion$4.31 million-2.15
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$54.32+3.4%$3.93 billion$117.91 million-11.02
LEGN
Legend Biotech
1.3$30.35+2.7%$3.93 billion$64.39 million0.00
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$61.23+2.4%$3.80 billion$806.43 million-8.67Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$23.70+7.7%$3.80 billion$204.89 million-29.63
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$46.59+0.1%$3.75 billionN/A-6.28
Alkermes logo
ALKS
Alkermes
1.2$22.44+0.4%$3.60 billion$1.17 billion-48.78
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$115.68+0.4%$3.39 billionN/A-57.55Earnings Announcement
Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.57+3.9%$3.39 billion$114.62 million-7.49Earnings Announcement
Analyst Report
Analyst Revision
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.83+4.5%$3.34 billion$339.08 million-12.69Analyst Report
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$58.60+0.3%$3.15 billion$1.11 billion18.84Analyst Report
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$37.54+1.1%$3.05 billion$60,000.00-11.66Earnings Announcement
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$81.62+1.8%$3.01 billion$26.52 million-7.19Earnings Announcement
Arvinas logo
ARVN
Arvinas
1.7$63.01+2.7%$3.00 billion$42.98 million-24.61
Insmed logo
INSM
Insmed
1.2$26.46+1.9%$2.79 billion$136.47 million-10.18Earnings Announcement
Analyst Report
Unusual Options Activity
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.14+0.1%$2.76 billion$644.77 million-10.29Upcoming Earnings
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$38.29+1.2%$2.73 billion$306.98 million-5.48
MorphoSys logo
MOR
MorphoSys
0.3$19.95+2.0%$2.68 billion$80.43 million95.00News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$61.98+2.0%$2.67 billion$421.03 million21.82Analyst Report
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$41.61+1.1%$2.57 billionN/A-22.86Earnings Announcement
Gap Up
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$58.91+2.1%$2.49 billionN/A0.00
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.22+4.1%$2.45 billion$182.24 million-8.02Earnings Announcement
ALX Oncology logo
ALXO
ALX Oncology
1.9$54.68+10.8%$2.44 billionN/A0.00
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.7$20.61+0.8%$2.39 billion$306.49 million23.16Earnings Announcement
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.8$36.60+3.3%$2.35 billion$2.11 million-7.92Analyst Report
Analyst Revision
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$46.59+1.1%$2.35 billion$963.01 million14.47Earnings Announcement
Analyst Report
Analyst Revision
Cryoport logo
CYRX
Cryoport
1.7$51.27+10.3%$2.34 billion$33.94 million-88.40Analyst Report
Analyst Revision
Gap Down
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.